
News|Articles|February 1, 2007
February 2007 Oncology News International
Advertisement
Cover Story
- Pancreatic Ca Vaccine Extends Survival After Surgery
Focus on Lung Cancer
- BB-10901 Compound Delivers Potent Agent to CD56+ Tumors
- First-line Nab-paclitaxel Shows Efficacy in NSCLC Trials
Focus on Hematology
- High Response Rate for Lenalidomide Plus Melphalan and Prednisone in Newly Diagnosed Multiple Myeloma Patients
Cancer Care & Economics
- Billing Plans for Routine Care Essential When Patients Enroll in Clinical Trials
- RHIOs Allow Exchange of Electronic Info
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
3
What Do Physicians and Patients Think About ADCs as Cancer Treatment?
4
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
5



















































































